8-K: InMed Pharmaceuticals Reports Strong Revenue Growth and Advances Preclinical Programs in Q2 Fiscal 2024

InMed Pharmaceuticals announced a 164% revenue increase in its BayMedica subsidiary and progress in its Alzheimer's and Age-Related Macular Degeneration preclinical programs for the second quarter of fiscal year 2024.

Summary

• InMed Pharmaceuticals reported its financial results for the second quarter of fiscal year 2024, which ended December 31, 2023.
• The company's commercial subsidiary, BayMedica, experienced a 164% revenue growth compared to the same period last year, reaching $1.2 million for the quarter.
• InMed closed calendar year 2023 with a cash position of $9.5 million.
• The company is advancing two new preclinical programs, INM-901 for Alzheimer's disease and INM-089 for Age-Related Macular Degeneration (AMD).
• Preclinical studies for INM-901 have shown promising results in targeting multiple biological pathways associated with Alzheimer's, including neuroprotection and reduction in neuroinflammation.
• INM-089 is expected to enter Investigational New Drug (IND)-enabling studies in mid-2024, with an IND application anticipated in the first half of 2025.
• The company is seeking partnerships for the continued development of INM-755 for chronic itch.
• For the six months ended December 31, 2023, InMed recorded a net loss of $4.0 million, compared to a net loss of $5.6 million for the same period in 2022.
• Research and development expenses decreased to $1.9 million for the six months ended December 31, 2023, from $2.2 million in the prior year.
• General and administrative expenses also decreased to $2.7 million for the six months ended December 31, 2023, from $3.0 million in the prior year.
• The company's cash position increased to $9.5 million as of December 31, 2023, compared to $8.9 million at June 30, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, advancements in preclinical programs, and a decrease in net loss. The company's cash position is also healthy. However, the company is still in the early stages of drug development and faces risks associated with regulatory approvals and market fluctuations.

Positives

• BayMedica's revenue grew by 164% year-over-year, indicating strong commercial performance.
• The company's cash position of $9.5 million provides a solid financial base for future operations.
• The launch of two new preclinical programs in Alzheimer's and AMD demonstrates a commitment to innovation and addressing unmet medical needs.
• Preclinical results for INM-901 and INM-089 are promising, suggesting potential for effective treatments.
• The company's net loss decreased year-over-year, indicating improved financial management.
• The company successfully raised $5.2 million through a private placement.

Negatives

• The company recorded a net loss of $4.0 million for the six months ended December 31, 2023.
• The company expects revenue fluctuations to continue in future quarters.
• The company is still in the preclinical stage for its new drug programs, meaning there is still a long path to commercialization.

Risks

• The company's cash runway is expected to last into the third quarter of calendar year 2024, depending on the level and timing of BayMedica revenues and operating expenses.
• The development of pharmaceutical products is subject to regulatory approvals and clinical trial risks.
• The company's success depends on securing partnerships for the continued development of INM-755.
• The rare cannabinoids sector is subject to market fluctuations and competition.
• The company's future revenue is subject to fluctuations.

Future Outlook

The company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the third quarter of calendar year 2024, depending on the level and timing of BayMedica revenues and operating expenses. The company anticipates sustained volume growth over a 12-month period and expects to improve margins over time.

Management Comments

• Eric A. Adams, InMed Chief Executive Officer, commented, 'This period was another strong operational quarter for the Company, as we expanded our pharmaceutical pipeline with the launch of two new programs with a particular focus on proprietary small molecule drug development candidates.'
• Adams continued, 'Our commercial subsidiary, BayMedica LLC, continues to grow revenues, up 164% compared to the same three month period last year.'

Industry Context

This announcement highlights InMed's progress in the rare cannabinoid sector, which is gaining traction in both pharmaceutical and health and wellness markets. The company's focus on developing proprietary cannabinoid analogs and its commercial success with BayMedica position it well within this growing industry.

Comparison to Industry Standards

• The 164% revenue growth in BayMedica is significantly higher than the average growth rate seen in the broader cannabinoid market, suggesting a strong competitive position.
• The company's focus on preclinical programs for Alzheimer's and AMD aligns with the industry trend of exploring cannabinoid-based therapeutics for neurological and age-related diseases.
• Compared to companies like GW Pharmaceuticals (now Jazz Pharmaceuticals) which focused on clinical development of cannabinoid-based drugs, InMed is at an earlier stage with its preclinical programs, but has a strong commercial arm with BayMedica.
• Other companies like Canopy Growth and Aurora Cannabis have faced challenges in achieving profitability, while InMed is showing progress in reducing its net loss, indicating better financial management.

Stakeholder Impact

• Shareholders will be encouraged by the strong revenue growth and progress in preclinical programs.
• Employees may benefit from the company's growth and expansion.
• Customers of BayMedica will have access to a growing range of rare cannabinoid products.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• The company will continue preclinical studies for INM-901, including drug metabolism and pharmacokinetics.
• The company expects to initiate Investigational New Drug (IND)-enabling studies for INM-089 in mid-2024.
• The company will seek partnerships for the continued development of INM-755.
• The company will continue to focus on growing BayMedica's revenue and improving margins.

Key Dates

Keywords

cannabinoids, pharmaceuticals, Alzheimer's, Age-Related Macular Degeneration, BayMedica, preclinical, revenue, INM-901, INM-089, INM-755, clinical trials, rare cannabinoids